InnoCare Pharma (688428.SH) released its performance for the first three quarters, with a net profit attributable to shareholders of RMB 656 million, turning profitable year-on-year.

Zhitong Finance APP News, InnoCare Pharma (688428.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved revenue of 2.099 billion yuan, a year-on-year increase of 88.21%; net profit attributable to the parent company was 656 million yuan, turning from loss to profit year-on-year; net profit after deducting non-recurring gains and losses was 586 million yuan, turning from loss to profit year-on-year; basic earnings per share were 0.39 yuan.